Ocular therapy company Tarsius Pharma revealed on Monday the receipt of a highly competitive HRIZON 2020 Grant, valued at EUR2.4m, to support the first-in-human clinical trial of its novel drug TRS01.
The EUR2.4m HRIZON 2020 Grant was awarded by the European Commission.
According to the company, it implements a patented, proprietary new molecule to 're-engineer' the immune system. TRS, which is its bio-inspired technology, approaches inflammatory diseases from within the immune system and helps in treating blinding ocular diseases.
In addition, the company's TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases. Untreated, these diseases can have devastating effects and may eventually lead to blindness.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial